Results showed Orca’s treatment, a purified mix of donor-derived T cells and stem cells, was safer than standard transplant ...

From STAT’s Andrew Joseph: AstraZeneca said this morning it was buying the Belgian cell therapy company EsoBiotec for $425 ...

In a late-stage trial of patients with multiple types of blood cancer, Orca Bio’s allogeneic T-cell immunotherapy doubled the ...

Anthony Stein, MD, assessed total marrow and lymphoid irradiation with post-transplant cyclophosphamide in patients with ...

Theriva Biologics is putting more of its eggs in the VCN-01 basket as it unveils a change-up in its R&D focus. | Theriva ...

Allogene Therapeutics recently released exciting results from the Phase 1 ALPHA/ALPHA2 trials of the Allogeneic CAR T 'Cemacabtagene Ansegedleucel/ALLO-501' in Relapsed/Refractory Large B-Cell ...

Q2 2025 Earnings Conference Call February 26, 2025 5:00 PM ETCompany ParticipantsSilviu Itescu - Chief Executive ...

Further study is needed in larger populations to verify these outcomes. Despite recent advances, up to 40% of patients develop acute graft-versus-host disease (GVHD) after allogeneic transplant.

Following the transplant, they are given cyclophosphamide (a drug to prevent graft-versus-host disease, in which immune cells in the donor marrow attack their new host) and other drugs for up to one ...

Following the transplant, they are given cyclophosphamide (a drug to prevent graft-versus-host disease, in which immune cells in the donor marrow attack their new host) and other drugs for up to ...

Following the transplant, they are given cyclophosphamide (a drug to prevent graft-versus-host disease, in which immune cells in the donor marrow attack their new host) and other drugs for up to ...